AEON Biopharma, Inc. 8-K

What Happened
AEON Biopharma (AEON) announced the appointment of John Bencich as Chief Financial Officer (Board appointed March 6, 2026; effective as CFO March 9, 2026; principal financial officer effective April 1, 2026). The company filed employment agreements for Mr. Bencich and for Chief Accounting Officer Jennifer Sy, disclosed their compensation and severance terms, and adopted an amendment to its 2025 Employment Inducement Incentive Award Plan reserving an additional 1,000,000 shares for inducement awards (effective March 6, 2026).

Key Details

• CFO hire: John Bencich (age 49) — base salary $450,000; target annual cash bonus 40% of base.
• CFO equity: expected grant of 754,717 restricted stock units (RSUs) vesting 25% annually over 4 years, and 235,849 performance restricted stock units (PSUs) with staged vesting tied to NYSE American compliance milestones. Grants under AEON’s 2025 Inducement Plan.
• CFO severance: if terminated without cause or resigns for good reason — six months salary, 50% target bonus, six months health coverage and limited accelerated vesting; enhanced (12 months salary/100% bonus/12 months health) if termination occurs in close proximity to a change in control. Includes Section 280G “best pay” provision and a one‑year non‑solicit.
• Chief Accounting Officer: Jennifer Sy remains at $275,000 base and 30% target bonus; severance mirrors CFO terms (six months or 12 months in change‑in‑control window), two‑year non‑solicit, and 280G “best pay” protection. Good‑reason resignation rights for Ms. Sy begin after Sept 6, 2026.
• Inducement Plan amendment: board reserved an additional 1,000,000 Class A shares for awards under the Inducement Plan, adopted without stockholder approval under NYSE American rules. Filing states no related‑person transactions or family relationships connected to the CFO hire.

Why It Matters
This 8‑K signals AEON is strengthening its finance leadership ahead of regulatory and financing milestones by hiring an experienced biotech CFO and formalizing executive employment terms. Investors should note potential dilution from the new inducement‑plan reserve and the specific equity grants disclosed for the CFO. The disclosed severance and change‑in‑control protections are material to executive compensation governance; the 280G “best pay” clauses may affect post‑transaction payouts.